Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term vedolizumab IV extension study in pediatric ulcerative colitis or Crohn's disease
2023-509046-36-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (2 cohorts), sponsored by Takeda. Primary endpoints: Incidence of adverse events and Incidence of prespecified safety events. Planned start Apr 2023; status: authorised.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2023-509046-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509046-36-00.